OssDsign (OSSD) investor relations material

Executive summary

• Achieved SEK 180.2 million in net sales for the year, up 45% year-over-year at constant exchange rates, with reported growth impacted by U.S. dollar to SEK exchange rate fluctuations.

• Gross margin remained strong at 96.3% for both Q4 and the full year, exceeding previous guidance and reflecting strong product economics.

• Adjusted EBIT improved, with operational leverage and cost control, despite transition costs related to the CEO change.

• Published new clinical evidence supporting Catalyst's efficacy in challenging orthopedic cases, expanding potential applications.

• Expanded commercial footprint in the Western U.S. through new IDN agreements, opening significant growth opportunities.

Financial highlights

• Q4 net sales reached SEK 45.1 million, up 24% year-over-year at constant exchange rates, with full year sales at SEK 180.2 million, representing 45% growth.

• Q4 adjusted EBIT was SEK -9.4 million, a significant improvement from SEK -12.3 million in Q4 2024.

• Full-year net result was SEK -51.0 million, with EPS at SEK -0.5.

• Cash flow from operating activities for the year was SEK -64.0 million, or SEK -49.0 million adjusted for one-off LTIP and CEO transition costs.

• Cash and cash equivalents at year-end were SEK 191.3 million, bolstered by a SEK 158 million share issue in Q2.

Outlook and guidance

• Long-term target to exceed SEK 400 million in sales by 2028, with positive operating result and cash flow in the second half of the strategy period.

• Plans to double the U.S. sales team by end of Q1 2026 to accelerate growth.

• Continued investment in U.S. sales and marketing and clinical evidence generation to support market expansion.